Approval · Notice of Compliance 18129 · 2016
TALTZ: Notice of Compliance 18129
Issued May 25, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18129
- Date
- May 25, 2016
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- IXEKIZUMAB 80 MG per ML
- IXEKIZUMAB 80 MG per SYR